Table 1.
Comparison of clinical features of SARS-CoV-2, SARS-CoV and MERS-CoV.
| Classification | Original location | Epidemiology | Clinical symptoms | Incubation period | Total cases (global) | Total death (global) | Mortality | References | |
|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 | Beta-CoV | Wuhan, China | 2019–2020 in China Globally thereafter |
Fever, dry cough, dyspnea, myalgia, headache, diarrhea | 3–6 days | 18.4 million | 697 thousand | 3.8% | 31986264 |
| SARS-CoV | Beta-CoV | Guangdong, China | 2002–2003 in China Globally thereafter |
Fever, dry cough, dyspnea, myalgia, headache, diarrhea, malaise, respiratory distress | 2–11 days | 8096 | 774 | 9.6% | 12734147 |
| MERS-CoV | Beta-CoV | Jeddah, Saudi Arabia | 2012 in Middle East 2015 in South Korea |
Fever, cough, chills, sore throat, arthralgia, dyspnea, pneumonia, myalgia, diarrhea, vomiting | 2–13 days | 2519 | 866 | 34.3% | 26049252 |
MERS-CoV, Middle East Respiratory Syndrome Coronavirus; SARS-CoV, Severe Acute Respiratory Syndrome Coronavirus; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.